Juq-158 (480p 2027)

| Section | What to Include | Common Pitfalls | |--------|----------------|-----------------| | Abstract | Problem, method, result, impact | Too vague or overly detailed | | Introduction | Clear motivation, defined scope | Jargon without explanation | | Methodology | Replicable steps, rationale | Skipping critical parameters | | Results | Objective data, visual aids | Cherry‑picking favorable outcomes | | Discussion | Balanced interpretation, limitations | Over‑claiming significance | | Conclusion | Concise synthesis, future outlook | Introducing new data |

Next Steps

Good luck with JUQ‑158! If you need a more detailed write‑up for any specific section (e.g., a full literature review or a data analysis narrative), just let me know. JUQ-158

JUQ-158 is a mid-scope initiative focused on [feature/component/process X]. Its goal is to implement and validate a reliable solution that addresses performance, security, and maintainability concerns identified in the preceding assessment phase. | Section | What to Include | Common

| Technique | Performance | |-----------|-------------| | GC‑MS (EI) | Retention time ~ 12.3 min on DB‑5; major fragment m/z = 91 (tropylium ion), 149, 197. | | LC‑HRMS (ESI‑+ ) | Accurate mass m/z = 312.1642 ([M+H]⁺); typical product ions: m/z = 197.0915 (pyrrolidine fragment) and 150.0652 (fluorophenyl). | | Immunoassay | No cross‑reactivity with standard drug panels (opioid, amphetamine, cannabinoid). | | Portable Raman | Peaks at 1,025 cm⁻¹ (C‑F stretch) and 1,640 cm⁻¹ (C=C aromatic). | Next Steps

For laboratories, a validated LC‑MS/MS method (multiple‑reaction monitoring of the two product ions above) is now included in the EMCDDA NPS Reference Library (Version 3, 2025).